Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers.

INTRODUCTION: Frontline health care workers (HCW) have higher risk than the general population to become infected by SARS.CoV.2, so they were a priority group for Covid-19 vaccine administration. We compared the incidence and prevalence of HCW infected pre-and post-vaccination with the BNT162b2 mRNA COVID-19 vaccine. MATERIAL AND METHODS: Prospective observational study carried out between 01/12/20 and 07/03/21 in La Paz University Hospital, Madrid (Spain). SARS.CoV.2 positive cases in HCW after vaccination were collected and compared to those hospitalized COVID-19 patients at the same hospital. RESULTS: Two weeks after finishing the first round of vaccinations daily new cases of HCW infections (symptomatic and asymptomatic) decreased substantially and cumulative cases of infected HCW and hospitalized COVID-19 patients started to diverge. No new positive cases of HCW infection were registered seven days after the second dose of BNT162b2 mRNA COVID-19 vaccine. CONCLUSIONS: BNT162b2 mRNA COVID-19 vaccine is highly effective in Spanish HCW.

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers.

Introduction: Frontline health care workers (HCW) have higher risk than the general population to become infected by SARS.CoV.2, so they were a priority group for Covid-19 vaccine administration. We compared the incidence and prevalence of HCW infected pre-and post-vaccination with the BNT162b2 mRNA COVID-19 vaccine. Material and methods: Prospective observational study carried out between 01/12/20 and 07/03/21 in La Paz University Hospital, Madrid (Spain). SARS.CoV.2 positive cases in HCW after vaccination were collected and compared to those hospitalized COVID-19 patients at the same hospital. Results: Two weeks after finishing the first round of vaccinations daily new cases of HCW infections (symptomatic and asymptomatic) decreased substantially and cumulative cases of infected HCW and hospitalized COVID-19 patients started to diverge. No new positive cases of HCW infection were registered seven days after the second dose of BNT162b2 mRNA COVID-19 vaccine. Conclusions: BNT162b2 mRNA COVID-19 vaccine is highly effective in Spanish HCW.

Introducción: Los trabajadores sanitarios (TS) de primera línea tienen mayor riesgo de infectarse de SARS-CoV-2 que la población general, por lo que han sido un grupo prioritario para la vacunación frente a COVID-19. Comparamos la incidencia y prevalencia de TS infectados antes y después de la vacunación con BNT162b2 mRNA frente a COVID-19. Material y métodos: Estudio prospectivo observacional realizado entre 01 de diciembre de 2021 en el Hospital Universitario La Paz, Madrid, España. Se registraron los casos positivos para SARS-CoV-2 en TS y se compararon con los hospitalizados por COVID-19. Resultados: Dos semanas tras la primera ronda de vacunación las nuevas infecciones en TS (sintomáticas y asintomáticos) disminuyeron sustancialmente y los casos acumulados de TS infectados y pacientes hospitalizados por COVID-19 empezaron a divergir. No hubo nuevas infecciones en TS vacunados a los siete días de la segunda dosis de la vacuna. Conclusión: La vacuna BNT162b2 mRNA frente a SARS-CoV-2 es altamente eficaz en TS españoles.

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers.

INTRODUCTION: Frontline health care workers (HCW) have higher risk than the general population to become infected by SARS.CoV.2, so they were a priority group for Covid-19 vaccine administration. We compared the incidence and prevalence of HCW infected pre-and post-vaccination with the BNT162b2 mRNA COVID-19 vaccine. MATERIAL AND METHODS: Prospective observational study carried out between 01/12/20 and 07/03/21 in La Paz University Hospital, Madrid (Spain). SARS.CoV.2 positive cases in HCW after vaccination were collected and compared to those hospitalized COVID-19 patients at the same hospital. RESULTS: Two weeks after finishing the first round of vaccinations daily new cases of HCW infections (symptomatic and asymptomatic) decreased substantially and cumulative cases of infected HCW and hospitalized COVID-19 patients started to diverge. No new positive cases of HCW infection were registered seven days after the second dose of BNT162b2 mRNA COVID-19 vaccine. CONCLUSIONS: BNT162b2 mRNA COVID-19 vaccine is highly effective in Spanish HCW.

Reacciones adversas notificadas tras la administración de vacuna frente a Covid-19 en trabajadores de un hospital terciario / Adverse reactions reported after the vaccine administration against COVID-19 in workers of a terciary hospital

Objetivos: La enfermedad COVID-19 es una emergencia de salud pública de importancia internacional y la vacunación se plantea como la mejor herramienta contra esta. El objetivo de este estudio fue evaluar las posibles reacciones adversas a la vacuna frente al COVID-19 notificadas por los trabajadores de un hospital terciario de Madrid. Realizando una descripción de la frecuencia, la presencia en la ficha técnica, la asociación con los antecedentes de infección por SARS-COV-2 y la edad. Material y Métodos: Se realizó un análisis descriptivo retrospectivo de las posibles reacciones adversas notificadas al Servicio de Prevención de Riesgos Laborales del hospital tras la administración de las dos dosis de la vacuna para COVID-19 (Comirnaty®) en una muestra de 8446 trabajadores que recibieron la primera dosis y 8255 que recibieron la segunda. Se realizó un análisis comparativo aplicando la prueba Chi-cuadrado de Pearson para las variables cualitativas y el test de Mann-Whitney para variables cuantitativas. Resultados: Los trabajadores que notificaron reacciones adversas fueron 207 sujetos tras la dosis 1 (2,45% del total de vacunados) y 397 sujetos tras la dosis 2 (4,80% del total de vacunados). El 76,8% eran mayores de 55 años (dosis 1) y 15,9% con dosis 2. El 57% tenía síntomas que ya estaban descritos en la ficha técnica (dosis 1) y el 70,5% con dosis 2. El 50,7% habían sido diagnosticados COVID-19 previamente (dosis 1) y 30,5% con dosis 2. Conclusiones: Las reacciones adversas notificadas en nuestro estudio han sido leves o moderadas coincidiendo con los estudios consultados. Las reacciones adversas fueron más frecuentes tras la segunda dosis. Del grupo de trabajadores que notificaron reacciones adversas hubo más con antecedentes de COVID-19, sobre todo con la primera dosis. Deberá continuarse estudiando las reacciones producidas tras la vacunación y su relación de causalidad con ella (AU)

Objectives: The COVID-19 disease is a public health emergency of international importance and vaccination is considered the best tool against it. The objective of this study was to evaluate the possible adverse reactions to the vaccine against COVID-19 reported by workers at a tertiary hospital in Madrid. Making a description of the frequency, the presence in the technical sheet, the association with the history of infection by SARS-COV-2 and age. Material and Methods: A retrospective descriptive study of the possible adverse reactions reported to the Occupational Risk Prevention Service of the hospital after the administration of the two doses of the vaccine for COVID-19 (Comirnaty®) was carried out in a sample of 8446 workers that received the first dose 1 and 8255 that received the second. A comparative analysis was performed by applying Pearson’s Chi-square test for qualitative variables and the Mann-Whitney test for quantitative variables. Results: The subjects who reported adverse reactions were 207 after dose 1 (2.45% of total vaccinated) and 397 after dose 2 (4.80% of total vaccinated). 76.8% were older than 55 years (dose 1) and 15.9% with dose 2. 57% had symptoms that were already described in the technical data sheet (dose 1) and 70.5% with dose 2. 50.7% had been previously diagnosed with COVID-19 (dose 1) and 30.5% with dose 2. Conclusions: The adverse reactions reported in our study have been mild or moderate, coinciding with the studies consulted. Adverse reactions were more frequent after the second dose. Among the workers who reported adverse reactions, there were more with a history of COVID-19, especially after the first dose. The reactions produced after vaccination and their causal relationship with it should continue to be studied (AU)

Reinfección sars-cov-2 vs falso positivo en trabajadora sanitaria / SARS-CoV-2 reinfection vs. false positive in a health worker

Se describe un caso de una trabajadora sanitaria de 30 años de edad que presenta un cuadro compatible con reinfección por SARS-CoV-2 o con falso positivo de prueba diagnóstica de infección activa. Se presenta la secuencia temporal de pruebas realizadas y sintomatología presentada. Los primeros casos de enfermedad por SARS-CoV-2 se reportaron en diciembre de 2019 y hasta la fecha el conocimiento de las pruebas diagnósticas está en continua revisión (AU)

It is described a case of a 30-year-old health worker who presents a clinical state compatible with reinfection by SARS-CoV-2 or with a false positive diagnostic test for active infection. The temporal sequence of tests performed and symptoms presented are described. The first cases of SARS-CoV-2 disease were reported in December 2019 and to date, knowledge of the diagnostic tests is under continuous review (AU)